Liver cancer drug combo gets its second FDA rejection
The FDA has once again rejected HLB and Jiangsu Hengrui Pharmaceuticals' drug combination to treat the most common form of liver cancer. Korean biotech HLB and China-based Hengrui applied to market rivoceranib and camrelizumab as ...
The FDA has once again rejected HLB and Jiangsu Hengrui Pharmaceuticals' drug combination to treat the most common form of liver cancer.
Korean biotech HLB and China-based Hengrui applied to market rivoceranib and camrelizumab as ...
